Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer Cells
暂无分享,去创建一个
[1] Hyung-Mun Yun,et al. Latifolin, a Natural Flavonoid, Isolated from the Heartwood of Dalbergia odorifera Induces Bioactivities through Apoptosis, Autophagy, and Necroptosis in Human Oral Squamous Cell Carcinoma , 2022, International journal of molecular sciences.
[2] N. Zaffaroni,et al. Necroptosis and Prostate Cancer: Molecular Mechanisms and Therapeutic Potential , 2022, Cells.
[3] B. Yousefi,et al. The role of polyphenols in overcoming cancer drug resistance: a comprehensive review , 2022, Cellular & molecular biology letters.
[4] F. Bray,et al. Epidemiology and Prevention of Prostate Cancer. , 2021, European urology oncology.
[5] M. Barakat,et al. Targeting Drug Chemo-Resistance in Cancer Using Natural Products , 2021, Biomedicines.
[6] N. Zaffaroni,et al. δ‐Tocotrienol sensitizes and re‐sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK‐mediated apoptosis , 2021, Cell proliferation.
[7] M. Ashrafizadeh,et al. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[8] Yoon-Jin Lee,et al. Curcumin Targets Both Apoptosis and Necroptosis in Acidity-Tolerant Prostate Carcinoma Cells , 2021, BioMed research international.
[9] Sayeon Cho,et al. The role of epithelial–mesenchymal transition-regulating transcription factors in anti-cancer drug resistance , 2021, Archives of Pharmacal Research.
[10] Y. Assaraf,et al. Therapeutic strategies to overcome taxane resistance in cancer. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[11] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[12] T. Efferth,et al. Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through Necroptosis , 2021, Cancers.
[13] S. Manickam,et al. Stable W/O/W multiple nanoemulsion encapsulating natural tocotrienols and caffeic acid with cisplatin synergistically treated cancer cell lines (A549 and HEP G2) and reduced toxicity on normal cell line (HEK 293). , 2021, Materials science & engineering. C, Materials for biological applications.
[14] Yoon-Jin Lee,et al. Synergistic anticancer activity of resveratrol in combination with docetaxel in prostate carcinoma cells , 2020, Nutrition research and practice.
[15] J. Teishima,et al. Molecular mechanisms of docetaxel resistance in prostate cancer , 2020, Cancer drug resistance.
[16] Subash C. Gupta,et al. Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. , 2020, Seminars in cancer biology.
[17] R. Mohammadinejad,et al. Curcumin in cancer therapy: A novel adjunct for combination chemotherapy with paclitaxel and alleviation of its adverse effects. , 2020, Life sciences.
[18] Yihua Wang,et al. The importance of epithelial-mesenchymal transition and autophagy in cancer drug resistance , 2020, Cancer drug resistance.
[19] K. Strebhardt,et al. Caspase-8: The double-edged sword. , 2020, Biochimica et biophysica acta. Reviews on cancer.
[20] D. Michaelis,et al. γ-Tocotrienol and α-Tocopherol Ether Acetate Enhance Docetaxel Activity in Drug-Resistant Prostate Cancer Cells , 2020, Molecules.
[21] W. Stone,et al. Upregulation of pERK and c-JUN by γ-tocotrienol and not α-tocopherol are essential to the differential effect on apoptosis in prostate cancer cells , 2019, BMC Cancer.
[22] M. Nieto,et al. A gene regulatory network to control EMT programs in development and disease , 2019, Nature Communications.
[23] Wei Zhang,et al. Celastrol Induces Necroptosis and Ameliorates Inflammation via Targeting Biglycan in Human Gastric Carcinoma , 2019, International journal of molecular sciences.
[24] R. Banjerdpongchai,et al. Goniothalamin Induces Necroptosis and Anoikis in Human Invasive Breast Cancer MDA-MB-231 Cells , 2019, International journal of molecular sciences.
[25] N. Luo,et al. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells , 2019, Biological Research.
[26] Chao Yang,et al. The role of necroptosis in cancer biology and therapy , 2019, Molecular Cancer.
[27] J. Clements,et al. Gamma-Tocotrienol Induces Apoptosis in Prostate Cancer Cells by Targeting the Ang-1/Tie-2 Signalling Pathway , 2019, International journal of molecular sciences.
[28] X. Tian,et al. Bufalin engages in RIP1-dependent and ROS-dependent programmed necroptosis in breast cancer cells by targeting the RIP1/RIP3/PGAM5 pathway. , 2019, Anti-cancer drugs.
[29] P. Limonta,et al. δ‐Tocotrienol induces apoptosis, involving endoplasmic reticulum stress and autophagy, and paraptosis in prostate cancer cells , 2019, Cell proliferation.
[30] G. Sethi,et al. Molecular Mechanisms of Action of Tocotrienols in Cancer: Recent Trends and Advancements , 2019, International journal of molecular sciences.
[31] Chaoyue Sun,et al. Phytochemicals: Current strategy to sensitize cancer cells to cisplatin. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[32] P. Limonta,et al. Tocotrienols and Cancer: From the State of the Art to Promising Novel Patents. , 2019, Recent patents on anti-cancer drug discovery.
[33] H. Loh,et al. Tocotrienols Modulate a Life or Death Decision in Cancers , 2019, International journal of molecular sciences.
[34] P. Limonta,et al. Anticancer properties of tocotrienols: A review of cellular mechanisms and molecular targets , 2018, Journal of cellular physiology.
[35] A. Ceribelli,et al. Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC , 2018, AntiCancer Research.
[36] R. DePinho,et al. Genetics and biology of prostate cancer , 2018, Genes & development.
[37] Fabrizio Fontana,et al. Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells , 2018, Cell Death & Disease.
[38] P. Limonta,et al. Semi-preparative HPLC purification of δ-tocotrienol (δ-T3) from Elaeis guineensis Jacq. and Bixa orellana L. and evaluation of its in vitro anticancer activity in human A375 melanoma cells , 2018, Natural product research.
[39] Wei Li,et al. Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies , 2018, Acta pharmaceutica Sinica. B.
[40] A. Qureshi,et al. Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs , 2018, Lipids in Health and Disease.
[41] A. Kunnumakkara,et al. Tocotrienols: The promising analogues of vitamin E for cancer therapeutics , 2018, Pharmacological research.
[42] N. Kyprianou,et al. Profiling Prostate Cancer Therapeutic Resistance , 2018, International journal of molecular sciences.
[43] R. Kaur,et al. Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer , 2017, British Journal of Cancer.
[44] T. Yano,et al. Combination Effect of δ-Tocotrienol and γ-Tocopherol on Prostate Cancer Cell Growth. , 2017, Journal of nutritional science and vitaminology.
[45] J. Yustein,et al. International Journal of Molecular Sciences Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue , 2022 .
[46] P. Kantoff,et al. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression , 2016, Proceedings of the National Academy of Sciences.
[47] H. Klocker,et al. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer , 2015, Oncotarget.
[48] T. Yano,et al. Annatto Tocotrienol Induces a Cytotoxic Effect on Human Prostate Cancer PC3 Cells via the Simultaneous Inhibition of Src and Stat3. , 2015, Journal of nutritional science and vitaminology.
[49] J. Fitzpatrick,et al. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. , 2014, European urology.
[50] A. A. Martens,et al. The multiple facets of drug resistance: one history, different approaches , 2014, Journal of experimental & clinical cancer research : CR.
[51] F. Rizzi,et al. Polyphenon E(R), a standardized green tea extract, induces endoplasmic reticulum stress, leading to death of immortalized PNT1a cells by anoikis and tumorigenic PC3 by necroptosis. , 2014, Carcinogenesis.
[52] E. Gallardo,et al. Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer , 2014, Molecular Cancer Therapeutics.
[53] D. Zuo,et al. The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis , 2013, BMC Cancer.
[54] Z. Huang,et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment , 2013, Cell Death and Disease.
[55] M. Azuma,et al. γ-tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the downregulation of the expression of NF-κB-regulated anti-apoptotic gene products , 2012, International journal of oncology.
[56] D. Green,et al. RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts. , 2011, Molecular cell.
[57] Y. Yap,et al. Gamma‐tocotrienol as an effective agent in targeting prostate cancer stem cell‐like population , 2010, International journal of cancer.
[58] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[59] Y. Imai,et al. A mutation in β‐tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel‐resistant prostate cancer cell line , 2010, Cell biology international.
[60] I. Tannock,et al. Chemotherapy for patients with hormone-refractory prostate cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[61] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[62] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.